Tunlametinib not checked
Shanghai Kechow Pharma, Inc. · HL-085
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens. IIb: HL-085 at the recommended dose or dosage regimen.”In the company’s words, NCT05331105 on ClinicalTrials.gov
- Tested for
- Colorectal Cancer Metastatic, Melanoma, Neurofibromatosis 1, Plexiform Neurofibromas
- Main trialPhase 3
- “This is a multicenter, randomized, open-label, Phase 3 study”In the company’s words, NCT06008119 on ClinicalTrials.gov
- Other names
- HL-085
Other drugs for Colorectal Cancer Metastatic
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up2
- 24 DecPhase 3 trial completes · ClinicalTrials.gov
- 22 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 24 Dec 2026 | Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | |
| Phase 3Recruiting | 22 Sep 2027 | Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma | |
| Phase 2Recruiting | 30 Oct 2025 | HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | |
| Phase 2Completed | 19 Feb 2023 | HL-085 in NRAS-mutated Advanced Melanoma | |
| Phase 2Unknown | 20 Jan 2024 | Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) | |
| Phase 2Unknown | 30 Sep 2024 | HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation | |
| Phase 1/2Completed | 18 Jan 2021 | Study of HL-085 in NRAS Mutant Advanced Melanoma | |
| Phase 1Terminated | 20 Jul 2021 | Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | |
| Phase 1Completed | 15 Sep 2022 | Study of HL-085 in Patients With Advanced Solid Tumor Tumors | |
| Phase 1Unknown | 1 Dec 2023 | A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026